DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells

BACKGROUND: H3K27M-mutated DMGs express high levels of the disialoganglioside GD2 and GD2-CAR T-cells (GD2-CART) regress DMG in preclinical models. METHODS: NCT04196413 is a 3 + 3 Phase I dose escalation trial testing GD2-CART in patients with biopsy-proved H3K27M DMG, with dose-limiting toxicities...

Descripción completa

Detalles Bibliográficos
Autores principales: Monje, Michelle, Majzner, Robbie, Mahdi, Jasia, Ramakrishna, Sneha, Patel, Shabnum, Chinnasamy, Harshini, Yeom, Kristen, Schultz, Liora, Barsan, Valentin, Richards, Rebecca, Campen, Cynthia, Reschke, Agnes, Toland, Angus Martin, Baggott, Christina, Mavroukakis, Sharon, Egeler, Emily, Moon, Jennifer, Jacobs, Ashley, Yamabe-Kwong, Karen, Rasmussen, Lindsey, Nie, Esther, Green, Sean, Kunicki, Michael, Fujimoto, Michele, Ehlinger, Zach, Reynolds, Warren, Prabhu, Snehit, Warren, Katherine E, Cornell, Tim, Partap, Sonia, Fisher, Paul, Grant, Gerald, Vogel, Hannes, Sahaf, Bita, Davis, Kara, Feldman, Steven, Mackall, Crystal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Diffuse Midline Glioma/DIPG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164854/
http://dx.doi.org/10.1093/neuonc/noac079.072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164854/
http://dx.doi.org/10.1093/neuonc/noac079.072

Ejemplares similares